Advances in Predictive Biomarkers for Immune Checkpoint Inhibitors in Lung Cancer: Why, Who, and How

Review this program to get up to date on the latest data informing optimal integration of immunotherapy biomarkers into the management of patients with lung cancer including an on-demand Webcast capturing discussion by medical oncology and pathology experts from a symposium at the 2019 Clinical Pathology meeting and downloadable slidesets.

Share

Program Content

Activities

ICIs Across Lung Cancer
The Why and Who: Overview of Immune Checkpoint Blockade in Lung Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: November 05, 2019

Expires: November 03, 2020

PD-L1 and Molecular Testing in Lung Cancer
The How: Current Predictors of Response to Immune Checkpoint Inhibitors
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: November 05, 2019

Expires: November 03, 2020

Emerging ICI Biomarkers
The Future: Opportunities for Predictive Biomarkers for Cancer Immunotherapy
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: November 05, 2019

Expires: November 03, 2020

No activities added yet

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Bristol Myers Squibb

Genentech TEXT Only

Merck Sharp & Dohme Corp.